Banerjee Tanushree, Kim S Joseph, Astor Brad, Shafi Tariq, Coresh Josef, Powe Neil R
Department of Medicine, University of California and San Francisco General Hospital, San Francisco, CA.
Department of Medicine, University Health Network, University of Toronto, Toronto, Canada.
Am J Kidney Dis. 2014 Dec;64(6):954-61. doi: 10.1053/j.ajkd.2014.07.010. Epub 2014 Sep 27.
Few reports have shown an association between access type and inflammatory marker levels in a longitudinal cohort. We investigated the role of access type on serial levels of inflammatory markers and the role of inflammatory markers in mediating the association of access type and risk of mortality in a prospective study of incident dialysis patients.
Cohort study, post hoc analysis of the CHOICE (Choices for Healthy Outcomes in Caring for ESRD) Study.
SETTING & PARTICIPANTS: In 583 participants, inflammation was assessed by measuring serum C-reactive protein (CRP) and interleukin 6 (IL-6) after access placement and at multiple times during 3 years' follow-up. Type of access was categorized as central venous catheter (CVC), arteriovenous graft (AVG), and arteriovenous fistula (AVF), and changes over time were recorded.
Access type, age, sex, race, body mass index, diabetes, cardiovascular disease, and serum albumin level.
CRP level, IL-6 level, and mortality.
We used mixed-effects pattern mixture models to study the association between access type and repeated measurements of inflammation and survival analysis to investigate the association of access type and mortality, adjusting for predictors.
In a mixed-effects pattern mixture model, compared with AVFs, the presence of CVCs and AVGs was associated with 62% (P=0.02) and 30% (P=0.05) increases in average CRP levels, respectively. A Cox proportional hazards model yielded nonsignificant associations of CVC and AVG use (vs AVFs) with risk of mortality when adjusted for inflammatory marker levels. Higher CRP levels were associated with increased risk of CVC failure than lower CRP levels.
CRP and IL-6 measurements not performed for all hemodialysis patients.
CVCs, compared with AVFs, are associated with a greater state of inflammation in incident hemodialysis patients, and the association of catheter use and mortality may be mediated by access-induced inflammation. Our findings support recommendations for the early removal or avoidance of CVC placements.
很少有报告显示在纵向队列研究中通路类型与炎症标志物水平之间存在关联。在一项针对新入组透析患者的前瞻性研究中,我们调查了通路类型对炎症标志物系列水平的作用,以及炎症标志物在介导通路类型与死亡风险关联中的作用。
队列研究,对CHOICE(关爱终末期肾病患者的健康结局选择)研究进行事后分析。
在583名参与者中,在通路置入后及3年随访期间多次测量血清C反应蛋白(CRP)和白细胞介素6(IL-6)以评估炎症情况。通路类型分为中心静脉导管(CVC)、动静脉移植物(AVG)和动静脉内瘘(AVF),并记录随时间的变化。
通路类型、年龄、性别、种族、体重指数、糖尿病、心血管疾病和血清白蛋白水平。
CRP水平、IL-6水平和死亡率。
我们使用混合效应模式混合模型研究通路类型与炎症重复测量之间的关联,并使用生存分析来研究通路类型与死亡率之间的关联,同时对预测因素进行调整。
在混合效应模式混合模型中,与AVF相比,CVC和AVG的存在分别使平均CRP水平升高62%(P=0.02)和30%(P=0.05)。在调整炎症标志物水平后,Cox比例风险模型显示使用CVC和AVG(与AVF相比)与死亡风险之间无显著关联。较高的CRP水平比较低的CRP水平与CVC失功风险增加相关。
并非所有血液透析患者都进行了CRP和IL-6测量。
与AVF相比,CVC与新入组血液透析患者的炎症状态更相关,导管使用与死亡率之间的关联可能由通路诱导的炎症介导。我们的研究结果支持早期移除或避免置入CVC的建议。